Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

Healthcare Medical Devices
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

NetraMark Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(127)
•••
Post by SkywalkerofLukeon Nov 05, 2021 3:48pm
88 Views
Post# 34093893

Interview with $MEND CEO

Interview with $MEND CEO

Found this recent interview with the CEO of $MEND $MEND.c along with one of their celebrity advisors, professional hockey player James Van Riemsdyk.


Discusses 


- Nuro app and what makes it unique

- Plans for the future

- Van Riemsdyk’s belief in the app and its tech

- How $MEND looks to address a gap in the mental health sector

- Etc. 


MEND chart clearly showing a falling wedge here. RSI trending higher and >50 - very positive MACD. Looking primed to break out any time. Will be keeping an eye here. 


https://cheddar.com/media/nuro-app-digitizes-experience-of-seeing-a-neurologist?mc_cid=8e9d5aa6cc&mc_eid=UNIQID

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities